Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Elizabeth Berry-Kravis, Vincent Des Portes, Randi J Hagerman, Sébastien Jacquemont, Perrine Charles, Jeannie Visootsak, Marc Brinkman, Karin Rerat, Barbara Koumaras, Liansheng Zhu, Gottfried Maria Barth, Thomas Jaecklin, George Apostol, Florian Von Raison

Research output: Contribution to journalArticlepeer-review

164 Scopus citations


Fragile X syndrome (FXS), the most common cause of inherited intellectual disability and autistic spectrum disorder, is typically caused by transcriptional silencing of the X-linked FMR1 gene. Work in animal models has described altered synaptic plasticity, a result of the up-regulation of metabotropic glutamate receptor 5 (mGluR5)-mediated signaling, as a putative downstreameffect. Post hoc analysis of a randomized, placebo-controlled, crossover phase 2 trial suggested that the selective mGluR5 antagonist mavoglurant improved behavioral symptoms in FXS patients with completely methylated FMR1 genes. We present the results of two phase 2b, multicenter, randomized, double-blind, placebocontrolled, parallel-group studies of mavoglurant in FXS, designed to confirmthis result in adults (n = 175, aged 18 to 45 years) and adolescents (n = 139, aged 12 to 17 years). In both trials, participants were stratified by methylation status and randomized to receive mavoglurant (25, 50, or 100 mg twice daily) or placebo over 12 weeks. Neither of the studies achieved the primary efficacy end point of improvement on behavioral symptoms measured by the Aberrant Behavior Checklist-Community Edition using the FXS-specific algorithm (ABC-CFX) after 12 weeks of treatment with mavoglurant. The safety and tolerability profile of mavoglurant was as previously described, with fewadverse events. Therefore, under the conditions of our study, we could not confirmthemGluR theory of FXS nor the ability of the methylation state of the FMR1 promoter to predictmavoglurant efficacy. Preclinical results suggest that future clinical trials might profitably explore initiating treatment in a younger population with longer treatment duration and longer placebo run-ins and identifying new markers to better assess behavioral and cognitive benefits.

Original languageEnglish (US)
Article number321ra5
JournalScience Translational Medicine
Issue number321
StatePublished - Jan 13 2016

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials'. Together they form a unique fingerprint.

Cite this